Clinical Trial: Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06960382) titled 'Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma' on March 25.

Brief Summary: The goal of this clinical trial is to evaluate the safety and tolerability of intralymphatic immunotherapy (ILIT) with ALUTARD SQ Felis domesticus in patients with cat allergy-induced allergic rhinitis and asthma. The main questions it aims to answer are:

Is ILIT with ALUTARD SQ Felis domesticus safe and well tolerated?

What immunological responses play a role in ILIT?

Researchers will compare the effects of ILIT to existing subcutaneous immunotherapy (SCIT) approaches to assess sa...